Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080492 | 0.90 | CYP3A4 (0.39) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL4127698 | 0.83 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL29583645 | 0.81 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL2912786 | 0.80 | SMYD2 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL4121310 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL20446429 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL31163018 | 0.80 | SMYD2 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL29598242 | 0.80 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2ABL1 | |
| SCHEMBL2912500 | 0.79 | OPRL1 (0.38) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL22929403 | 0.78 | MAPK1 (0.40) | CYP3A4HTTSMN1; SMN2ABL1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| EP-3143007-B1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CCNI, H1-0, H1-3 | CYP3A4 2381/4885HTT 2581/4885SMN1; SMN2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.